Aging and malignant hemopathies

Bron, Dominique; Adès, Lionel; Fülöp, Tamás; Goede, Valentin

doi:10.3324/haematol.2014.117721

Cited by 7 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[3][4][5][6][7] Similarly to the situation in several other types of cancers, management of older MM patients is more demanding due to their often impaired organ function, underlying comorbidities, and co-existing frailty, which may increase therapy-related toxicity, and lead to dose reduction and shorter treatment endurance. 3,4,[6][7][8][9] The high prevalence of geriatric impairments is increasingly being recognized, but is not always easily detectable without an objective assessment. 3,6,7 Our goal today involves reducing the risk of under-treating fit patients and overtreating those who are frail.…”

Section: Introductionmentioning

confidence: 99%

“…6,7,11,12,17 While these GAtools have been established and validated, their execution is time-consuming, an additional workforce is needed, and the involvement of a geriatric team is advisable. 6,7,9,11,12,17 Whether shorter frailty scores in cancer patients may substitute and/or add to GA-tools is being pursued in single-and multi-center trials ( Table 1).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age

et al. 2020

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age

et al. 2020

View full text Add to dashboard Cite

“…Biomarkers of frailty specifically in CLL are also lacking. A CLL consensus initiative is in progress to help guide CLL-specific fitness scoring [27].…”

Section: Introductionmentioning

confidence: 99%

Age-related changes in the BACH2 and PRDM1 genes in lymphocytes from healthy donors and chronic lymphocytic leukemia patients

et al. 2019

View full text Add to dashboard Cite

BackgroundAge-related genetic changes in lymphocyte subsets are not currently well documented. BACH2 is a transcription factor that plays an important role in immune-mediated homeostasis by tightly regulating PRDM1 expression in both B-cells and T-cells. BACH2 gene expression is highly sensitive to DNA damage in aged mice. This concept led us to investigate the variation in BACH2 and also PRDM1 expression in major lymphocyte subsets with age.MethodsLymphocyte subsets from 60 healthy donors, aged from 20 to 90 years, and 41 untreated chronic lymphocytic leukemia patients were studied. BACH2 and PRDM1 gene expression was analyzed by real-time quantitative PCR. BACH2 gene expression was correlated with its protein expression. Lymphocyte apoptosis was evaluated after intracellular oxidative stress-inducing etoposide treatment of T and B cells.ResultsOur analysis shows BACH2 mRNA downregulation with age in healthy donor CD4+, CD8+ T-cells and CD19+ B-cells. Decreased BACH2 expression was also correlated with an age-related reduction in CD8 + CD28+ T-cells. We found a strong correlation between age-related BACH2 downregulation and decreased CD4+ T-cell and CD19+ B-cell apoptosis. PRDM1, as expected, was significantly upregulated in CD4+ T-cells, CD8+ T-cells and CD19+ B-cells, and inversely correlated with BACH2. A comparison of untreated chronic lymphocytic leukemia patients with age-matched healthy donors reveals that BACH2 mRNA expression was further reduced in CD4+ T-cells, CD8+ T-cells and leukemic-B cells. PRDM1 gene expression was consequently significantly upregulated in CD4+ and CD8+ T-cells in chronic lymphocytic leukemia patients but not in their leukemic B-cells.ConclusionOverall, our data suggest that BACH2 and PRDM1 genes are significantly correlated with age in human immune cells and may be involved in immunosenescence.Electronic supplementary materialThe online version of this article (10.1186/s12885-019-5276-2) contains supplementary material, which is available to authorized users.

show abstract

“…Additionally, the patient's wishes and their capacity to understand the therapeutic approach should be fully integrated in the geriatric assessment. 9 A modern approach thus consists in the assessment of the patient's physiological age. 10 In this setting, geriatricians are essential collaborators, proposing various tools to evaluate physical performance (PS, Up and Go test, ADL, IADL, etc.…”

Section: Assessment Of "Physiological" Agementioning

confidence: 99%